Otsuka Pharmaceutical Co., Ltd. (Tokyo); The National Cancer Center Japan (Tokyo); Kyushu University (Fukuoka); Kyoto University (Kyoto); Nagoya Medical Center (Aichi); Advanced Clinical Research Center, The Institute of Medical Science at The University of Tokyo (Tokyo); and Keio University School of Medicine (Tokyo) announce today that Otsuka Pharmaceutical has received approval to manufacture and market HemeSight®, hematological malignancies gene panel test, in Japan. Otsuka will proceed on procedures to qualify HemeSight® for health insurance reimbursement and will start marketing the test as soon as launch preparations are completed.
